Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
Authors:
- Stefania FarcomeniSFStefania Farcomeni
- Sonia MorettiSMSonia Moretti
- Caterina FimianiCFCaterina Fimiani
- Lucia Fontanelli SulekovaLSLucia Fontanelli Sulekova
- Fenicia VescioFVFenicia Vescio
- Leonardo SernicolaLSLeonardo Sernicola
- Maria T. MaggiorellaMMMaria T. Maggiorella
- Anna Lisa RemoliARAnna Lisa Remoli
- Orietta PicconiOPOrietta Picconi
- Luciana MoscaLuciana Mosca
- Rozenn EsvanRERozenn Esvan
- Elisa BiliottiEBElisa Biliotti
Open Access
- 15 November 2021
- Vol. 10 (11) , 1488
Abstract
Background: Direct-acting antivirals (DAAs) treatment, although highly efficacious for the treatment of hepatitis C virus (HCV) infection, may not completely reconstitute the HCV-mediated dysregulated immune system, especially in patients co-infected with human immunodeficiency virus (HIV) and HCV. Objectives: We aimed to evaluate the impact of HCV eradication following DAA therapy on the immune system and liver disease improvement through comparative monitoring of 10 HCV mono-infected and 10 HCV/HIV co-infected patients under combined antiretroviral therapy (cART). Early and late longitudinal phenotypic changes in peripheral blood mononuclear cell (PBMC) subsets, T-cell activation, differentiation and exhaustion, as well as inflammatory biomarkers, indoleamine 2-3 dioxygenase (IDO) activity, and liver stiffness, APRI and FIB-4 scores were assessed. Materials and Methods: Samples were obtained at baseline (T0), week 1 (T1), week 2 (T2), week 12 (T3, end of treatment, EOT), and month 9 (T4, end of follow-up, 36 weeks post EOT). Results: All patients achieved a sustained virological response (SVR 12) after DAA treatment. Overall, changes of the T-cell immune phenotypes were greater in HCV/HIV co-infected than in HCV mono-infected, due to an increase in CD4+ and CD8+ T-cell percentages and of CD8+ T-cell activation and memory markers, in particular at the end of follow-up. On the other end, HCV mono-infected showed changes in the activation profile and in the memory CD4+ T-cell compartment. In HCV/HIV co-infected, a decrease in the IDO activity by DAA treatment was observed; conversely, in HCV mono-infected, it resulted unmodified. Regarding inflammatory mediators, viral suppression was associated with a reduction in IP-10 levels, while interferon regulatory factor (IRF)-7, interferon (IFN)-β, and interferon (IFN)-γ levels were downregulated during therapy and increased post therapy. A decrease in liver stiffness, APRI, and FIB-4 scores was also observed. Conclusions: Our study suggests that, although patients achieved HCV eradication, the immune activation state in both HCV mono-infected and HCV/HIV co-infected patients remains elevated for a long time after the end of DAA therapy, despite an improvement of liver-specific outcomes, meanwhile highlighting the distinct immunophenotypic and inflammatory biomarker profile between the groups of patients.Keywords
This publication has 39 references indexed in Scilit:
- Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Epidemiology of hepatitis C virus in HIV-infected patientsCurrent Opinion in HIV and AIDS, 2015
- Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus InfectionJournal of Innate Immunity, 2015
- Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited GuestsInternational Journal of Tryptophan Research, 2015
- Treatment of chronic hepatitis C in patients with HIV/HCV coinfectionWorld Journal of Virology, 2015
- IκB Kinase ε Targets Interferon Regulatory Factor 1 in Activated T LymphocytesMolecular and Cellular Biology, 2014
- Innate immunity and chronic immune activation in HCV/HIV-1 co-infectionClinical Immunology, 2010
- The role of chemokines as inflammatory mediators in chronic hepatitis C virus infectionJournal of Viral Hepatitis, 2007
- Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 2004
- Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?Immunology Today, 1999